Munich, Germany and San Francisco, USA, April 29, 2026 – CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, following the initiation of four late-stage clinical studies of its lead candidate, the GDF-15 inhibitor visugromab.

Munich, Germany and San Francisco, USA, April 23, 2026 – CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia International Trial, NCT07112196). The global study is evaluating the company's lead anti-GDF-15 antibody visugromab in patients with cancer-associated cachexia.

Munich, Germany and San Francisco, USA, April 7, 2026 – CatalYm today announced that the first patient has been dosed in the GDFATHER-HCC-01 trial (NCT07219459). The trial evaluates the company's lead anti-GDF-15 antibody visugromab in combination with chemoimmunotherapy as a second-line (2L) treatment for patients with unresectable or metastatic hepatocellular carcinoma (HCC).

Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG  ("MTx") today announced it has entered into a strategic collaboration and exclusive option-to-license agreement with CSL, a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases, for MTx's recombinant polyclonal IgG technology.

NEW YORK, January, 28th, 2026 – Sword Health, the world's leading AI Health company, today announced the acquisition of Kaia Health, a digital health company focused on musculoskeletal (MSK) and pulmonary care, in a deal valued at $285 million. The acquisition reinforces Sword's position as the fastest-growing AI Care platform in the world, expanding its ability to deliver high-quality, scalable care to new populations in the US while entering the German market.

Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces the publication of a qualitative research paper titled 'Development of a Conceptual Model of BKV Impacts on Health-Related Quality of Life in Kidney Transplant Recipients' in the Journal of Patient-Reported Outcomes.

Schlieren / Zurich, Switzerland, 18 December, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that the European Commission has granted orphan designation in the European Union (EU) for potravitug, a highly potent human BK polyomavirus ("BKPyV")-neutralizing antibody for the treatment of BKPyV infection in kidney transplant recipients.

Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the treatment of BK polyomavirus (BKPyV) infection in kidney transplant recipients (KTRs) at the American Society of Nephrology (ASN) Kidney Week Meeting from November 5–9, 2025, in Houston, Texas.

November 07, 2025 – Published at 9.00 am ET / 3.00 pm CET – We are excited to share that our Phase 1/2 GDFATHER-01 trial evaluating our lead candidate Visugromab in various solid tumor indications will be highlighted across multiple presentations at the upcoming SITC Annual Meeting 2025.

Munich, Germany and San Francisco, USA, October 20, 2025 – CatalYm today announced updated long-term data from its ongoing GDFATHER-1/2a trial (NCT04725474) at the European Society of Medical Oncology (ESMO) Congress 2025. The data provide further evidence that Growth Differentiation Factor-15 (GDF-15) blockade by visugromab can reverse resistance to PD-(L)1 treatment in patients with advanced solid tumors and deliver durable responses in patients who have relapsed or progressed on prior checkpoint inhibitor treatment.